<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67589">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02225951</url>
  </required_header>
  <id_info>
    <org_study_id>GDM.1.C/A</org_study_id>
    <nct_id>NCT02225951</nct_id>
  </id_info>
  <brief_title>Meal Tolerance Trial in Pregnant Women Diagnosed With Gestational Diabetes Mellitus.</brief_title>
  <acronym>GDM MTT</acronym>
  <official_title>A Randomised, Controlled, Open-label Trial to Investigate the Effect of a New Nutritional Supplement on Postprandial Glucose Response in Women Diagnosed With Gestational Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Asia Pacific Holdings Pte, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutricia Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danone Asia Pacific Holdings Pte, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is initiated to investigate the effect of a nutritional product on the 3-hr
      postprandial glucose response compared to a control standard breakfast at baseline and after
      4 weeks of intervention.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Feasibility of the current protocol is not optimal to further conduct the study.
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-hr postprandial glucose response</measure>
    <time_frame>28 days</time_frame>
    <description>To investigate the effect of a nutritional product on the 3-hr postprandial glucose response compared to a control standard breakfast at baseline and after 4 weeks of intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pregnant Women Diagnosed With Gestational Diabetes Mellitus.</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutritional product as breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional product</intervention_name>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard breakfast according to ADA recommendations</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant women, aged 18-40 years

          2. 18.5 kg/m2 &lt; pre-pregnancy BMI &lt; 27.5 kg/m2 [representing low to moderate risk
             category, adapted from WHO expert panel recommendation on BMI categories for
             determining public health and clinical action (REF: Lancet, 2004)]

          3. Singleton pregnancy

          4. Newly GDM diagnosed women between 24 to (the latest) 32 weeks of gestation;

          5. Diagnosed GDM according to either:

               -  World Health Organization (WHO) criteria if one or more glucose values equal to
                  or exceed these threshold values [75g Oral Glucose Tolerance Test: fasting 126
                  mg/dl; 2-h 140 mg/dl] or

               -  American Diabetic Association (ADA) criteria if two or more glucose values equal
                  to or exceed these threshold values [100g Oral Glucose Tolerance Test: fasting
                  95 mg/dl; 1-h 180 mg/dl; 2-h 155 mg/dl, 3-h 140/dl]

          6. Willing and able to comply with the protocol

          7. Signed informed consent

        Exclusion Criteria:

          1. Any gastrointestinal disease that interferes with bowel function and nutritional
             intake (i.e. constipation or diarrhea secondary to neuropathy, diarrhea due to
             chronic inflammatory bowel disease, gastroparesis, gastrectomy, galactosaemia,
             hyperemesis)

          2. Currently on anti-diabetic therapy, for example on insulin or oral anti-diabetic
             medication

          3. Already using a diabetes nutritional/dietary supplement (e.g. Glucerna®, Nutrient
             Diabetes®) within 4 weeks prior to signing informed consent

          4. Known allergy or intolerance for any of the following ingredients; fish, milk,
             protein, lactose, fiber or soy

          5. Any significant medical condition, other than GDM, that might interfere with the
             study or known to affect intra-uterine growth (e.g. Type 1 Diabetes, Type 2 Diabetes
             Mellitus, Crohn's disease, HIV/AIDS, liver disease, kidney disease etc.)

          6. Currently or previously on special low/no carbohydrate diet (e.g. Atkin's diet)
             within 8 weeks prior to signing informed consent

          7. Incapability to comply with study protocol or Investigator's uncertainty about the
             willingness or ability of the subject to comply with the protocol requirements

          8. Participation in other studies involving investigational or marketed products
             concomitantly or within 4 weeks prior signing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 20, 2014</lastchanged_date>
  <firstreceived_date>August 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
